<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="132429">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01377922</url>
  </required_header>
  <id_info>
    <org_study_id>LMS-002</org_study_id>
    <nct_id>NCT01377922</nct_id>
  </id_info>
  <brief_title>A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)</brief_title>
  <official_title>A Phase 3, Double-blind, Placebo-controlled, Randomized Discontinuation Study Followed by Open-label Extension Evaluating Efficacy and Safety of Amifampridine Phosphate in Patients With Lambert-Eaton Myasthenic Syndrome (LEMS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Catalyst Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Catalyst Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 3 study to evaluate the efficacy and safety of Amifampridine Phosphate in patients
      with Lambert-Eaton Myasthenic Syndrome (LEMS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This multicenter, double-blind, placebo-controlled, randomized (1:1) discontinuation study
      is a 4 part study designed to evaluate the efficacy and safety of multiple dose
      administration of amifampridine phosphate in patients with LEMS.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline Quantitative Myasthenia Gravis (QMG)at 14 days</measure>
    <time_frame>Assessment at Baseline, Day 8, and Day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in SGI score</measure>
    <time_frame>Assessment at Baseline, Days 8 &amp; 14</time_frame>
    <description>Subject Global Impression (SGI) is a measure of changes in subject's perception of change in overall wellbeing</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline Timed 25 Foot Walking Test (T25FW)at 14 days</measure>
    <time_frame>Assessment at Baseline, Day 8, and Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CGI-I score</measure>
    <time_frame>Baseline, Days 8 &amp; 14</time_frame>
    <description>Investigator perceived global improvement or change</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Lambert Eaton Myasthenic Syndrome</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo tablets administered 3-4 times a day over 2 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amifampridine Phosphate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Matching amifampridine phosphate tablets, 10 mg, administered 3-4 times a day for 2 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amifampridine Phosphate</intervention_name>
    <description>30-80 mg given 3-4 times per day with a maximum single dose of 20 mg (2 x 10 mg tablets).</description>
    <arm_group_label>Amifampridine Phosphate</arm_group_label>
    <other_name>3,4-diaminopyridine phosphate</other_name>
    <other_name>3,4-DAP phosphate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching number of tablets to the individual patient's tablet count of active at baseline.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: Individuals eligible to participate in this study must meet all of the
        following inclusion criteria:

          -  â‰¥18 years of age

          -  Confirmed diagnosis of LEMS

          -  Normal respiratory function

          -  Normal swallowing function

          -  If receiving peripherally acting cholinesterase inhibitors a stable dose is required
             for at least 7 days prior to Screening.

          -  If receiving oral immunosuppressants a stable dose is required for at least 90 days
             prior to Screening.

          -  Negative pregnancy test for females of childbearing potential

          -  If sexually active, willing to use 2 acceptable methods of contraception

          -  Willing to perform all study procedures as physically possible.

          -  Willing and able to provide written informed consent after the nature of the study
             has been explained and prior to the start of any research-related procedures.

        Exclusion Criteria: Individuals who meet any of the following exclusion criteria are not
        eligible to participate in the study:

          -  History of epilepsy or seizure.

          -  Known active brain metastasis.

          -  Use of Fampridine (4-aminopyridine), and any form of 3,4-diaminopyridine other than
             the IP provided, such as amifampridine base or Firdapse, during the study.

          -  Use of medications known to lower the epileptic threshold within 7 days or 5
             half-lives.

          -  Use of medications which inhibit neuromuscular junction function within 7 days or 5
             half-lives.

          -  Use of IVIG, plasmapheresis (plasma exchange), or immunoadsorption within 90 days

          -  Use of guanidine hydrochloride within 7 days

          -  Use of rituximab within 12 months

          -  History of drug allergy to any pyridine-containing substances or any amifampridine
             phosphate excipient(s).

          -  Use of any other investigational productwithin 30 days

          -  Treatment with a concomitant medication that prolongs the QT/QTc interval within 7
             days or 5 half-lives.

          -  Treatment with sultopride
             (4-amino-N-[(1-ethylpyrrolidin-2-yl)methyl]-5-ethylsulfonyl-2-methoxybenzamide)
             within 7 days.

          -  An abnormal electrocardiogram (ECG).

          -  Documented history of arrhythmias.

          -  History of additional risk factors for torsade de pointes.

          -  Breastfeeding or pregnant or planning to become pregnant (self or partner) at any
             time during the study.

          -  Likely or expected to require treatment for cancer within 3 months (90 days) after
             entering.

          -  History of severe renal impairment or evidence of severe renal impairment

          -  Any condition that places the patient at high risk of poor treatment compliance or of
             not completing the study.

          -  History of uncontrolled asthma.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles W Gorodetzky, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Chief Medical Officer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lyon</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>D-80336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>D-10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pecs</city>
        <zip>H-7623</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warsaw</city>
        <zip>02 097</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <zip>125367</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>Italy</country>
  </removed_countries>
  <verification_date>July 2016</verification_date>
  <lastchanged_date>July 26, 2016</lastchanged_date>
  <firstreceived_date>June 17, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Lambert-Eaton Myasthenic Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>3,4-diaminopyridine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
